BioWorld

Sep. 2, 2002

Summer Of Discontent Ending; Industry Aims For Fall Revival

Talk to enough buy-side analysts and industry boosters, and you're likely to come away with a strangely weary feeling. It's a feeling behind which lies suspicion and skepticism, a grave doubt about even the possibility of optimism. (Bioworld Financial Watch) Read More

Money Raised Year To Date

Stock Winners and Losers For The Week

Holiday Notice

Underwriters' Performance On IPOs From Jan. 1, 2002, To July 31, 2002: Full Credit To Lead Underwriter, Ranked By Gross Proceeds*

Underwriters' Performance On IPOs From Jan. 1, 2002, To July 31, 2002: Full Credit To Lead Underwriter, Ranked By After-Market Performance#

Underwriters' Performance On IPOs From Jan. 1, 2002, To July 31, 2002: Full Credit To All Underwriters, Ranked By Gross Proceeds*

Underwriters' Performance On IPOs From Jan. 1, 2002, To July 31, 2002: Full Credit To All Underwriters Ranked By After-Market Performance#

Underwriters' Performance On All Public Offerings From Jan. 1, 2002, To July 31, 2002: Full Credit To Lead Underwriter, Ranked By Gross Proceeds*

Underwriters' Performance On All Public Offerings From Jan. 1, 2002, To July 31, 2002: Full Credit To Lead Underwriter, Ranked By After-Market Performance#

Underwriters' Performance On All Public Offerings Jan. 1- July 31, 2002: Full Credit To All Underwriters, Ranked By Gross Proceeds*

Underwriters' Performance On All Public Offerings Jan. 1 - July 31, 2002: Full Credit To All Underwriters, Ranked By After-Market Performance*#

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

ASH 2025: Ianalumab data offer break from chronic ITP therapy

BioWorld

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...